AZD 4547

Drug Profile

AZD 4547

Alternative Names: AZD4547

Latest Information Update: 15 Jun 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Dust Diseases Authority; Institute of Respiratory Health; National Cancer Institute (USA); University of Glasgow; University of Wisconsin-Madison
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Non-small cell lung cancer
  • Phase II Breast cancer; Gastric cancer; Lung cancer; Mesothelioma; Oesophageal cancer
  • Phase I/II Glioblastoma; Solid tumours
  • Phase I Bladder cancer
  • Preclinical Head and neck cancer

Most Recent Events

  • 15 Jun 2017 Chemical structure information added
  • 01 Apr 2017 Preclinical trials in Head and neck cancer in USA (unspecified route) before April 2017
  • 01 Apr 2017 Pharmacokinetics and pharmacodynamics data from preclinical trial in Lung cancer and Head and Neck Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top